國立虎尾科技大學 |

Dyslipidemias = Pathophysiology, Evaluation and Management /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Dyslipidemias/ edited by Abhimanyu Garg.
其他題名:	Pathophysiology, Evaluation and Management /
其他作者:	Garg, Abhimanyu.
面頁冊數:	XVI, 525 p. 127 illus., 101 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Endocrinology . -
電子資源:	https://doi.org/10.1007/978-1-60761-424-1
ISBN:	9781607614241

Dyslipidemias = Pathophysiology, Evaluation and Management /
DyslipidemiasPathophysiology, Evaluation and Management /[electronic resource] :edited by Abhimanyu Garg. - 1st ed. 2015. - XVI, 525 p. 127 illus., 101 illus. in color.online resource. - Contemporary Endocrinology,2523-3785. - Contemporary Endocrinology,.

Lipoprotein Physiology -- Epidemiology of Blood Lipids and Lipoproteins -- Lipoprotein(a) -- Lipoproteins and Cardiovascular Disease Risk -- Detection and Treatment of Children and Adolescents with Dyslipidemia -- Type 2 Diabetes Mellitus and Dyslipidemia -- Type 1 Diabetes Mellitus and Dyslipidemia -- Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome -- Dyslipidemia in HIV-infected Patients -- Monogenic Hypercholesterolemia -- Primary Hypertriglyceridemia -- Genetic Disorders of HDL Metabolism -- Sitosterolemia and Other Rare Sterol Disorders -- Genetic Abetalipoproteinemia & Hypobetalipoproteinemia -- Drug-induced Dyslipidemia -- Lipodystrophies and Dyslipidemias -- Novel Genes for Dyslipidemias: Genome-Wide Association Studies -- Perspectives on Cholesterol Guidelines -- Nutrition and Coronary Heart Disease Prevention -- Phytosterol Therapy -- N-3 Fatty Acids: Role in Treating Dyslipidemias and Preventing Cardiovascular Disease -- Polyphenols for Cholesterol Management -- Dietary Supplements for Cholesterol Management -- Statins: Risk-Benefits and Role in Treating Dyslipidemias -- Fibrates: Risk-Benefits and Role in Treating Dyslipidemias -- Niacin: Risk-Benefits and Role in Treating Dyslipidemias -- Bile Acid Sequestrants: Risk-Benefits and Role in Treating Dyslipidemias -- Cholesterol Absorption Inhibitor-Ezetimibe: Risk-Benefits and Role in Treating Dyslipidemias -- Low Density Lipoprotein (LDL) Apheresis -- Novel Lipid Lowering Agents.

Dyslipidemias: Pathophysiology, Evaluation and Management provides a wealth of general and detailed guidelines for the clinical evaluation and management of lipid disorders in adults and children. Covering the full range of common through rare lipid disorders, this timely resource offers targeted, practical information for all clinicians who care for patients with dyslipidemias, including general internists, pediatric and adult endocrinologists, pediatricians, lipidologists, cardiologists, internists, and geneticists. For the last twenty years, there has been a growing recognition worldwide of the importance of managing dyslipidemia for the primary and secondary prevention of atherosclerotic vascular disease, especially coronary heart disease. This has been mainly due to the publication of the guidelines of National Cholesterol Education Program’s Adult Treatment Panel and Pediatric Panel from the United States. These guidelines have stimulated generation of similar recommendations from all over the world, particularly Europe, Canada, Australia and Asia. Developed by a renowned group of leading international experts, the book offers state-of-the-art chapters that are peer-reviewed and represent a comprehensive assessment of the field. A major addition to the literature, Dyslipidemias: Pathophysiology, Evaluation and Management is a gold-standard level reference for all clinicians who are challenged to provide the best care and new opportunities for patients with dyslipidemias.

ISBN: 9781607614241

Standard No.: 10.1007/978-1-60761-424-1doiSubjects--Topical Terms:

1254221
Endocrinology .

LC Class. No.: RC648-665.2

Dewey Class. No.: 616.4

Dyslipidemias = Pathophysiology, Evaluation and Management /
LDR:04368nam a22004095i 4500 001 965314
003 DE-He213
005 20200701111023.0
007 cr nn 008mamaa
008 201211s2015 xxu| s |||| 0|eng d
020 $a 9781607614241 $9 978-1-60761-424-1
024 7 $a 10.1007/978-1-60761-424-1 $2 doi
035 $a 978-1-60761-424-1
050 4 $a RC648-665.2
072 7 $a MJG $2 bicssc
072 7 $a MED027000 $2 bisacsh
072 7 $a MJG $2 thema
082 0 4 $a 616.4 $2 23
245 1 0 $a Dyslipidemias $h [electronic resource] : $b Pathophysiology, Evaluation and Management / $c edited by Abhimanyu Garg.
250 $a 1st ed. 2015.
264 1 $a Totowa, NJ : $b Humana Press : $b Imprint: Humana, $c 2015.
300 $a XVI, 525 p. 127 illus., 101 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Contemporary Endocrinology, $x 2523-3785
505 0 $a Lipoprotein Physiology -- Epidemiology of Blood Lipids and Lipoproteins -- Lipoprotein(a) -- Lipoproteins and Cardiovascular Disease Risk -- Detection and Treatment of Children and Adolescents with Dyslipidemia -- Type 2 Diabetes Mellitus and Dyslipidemia -- Type 1 Diabetes Mellitus and Dyslipidemia -- Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome -- Dyslipidemia in HIV-infected Patients -- Monogenic Hypercholesterolemia -- Primary Hypertriglyceridemia -- Genetic Disorders of HDL Metabolism -- Sitosterolemia and Other Rare Sterol Disorders -- Genetic Abetalipoproteinemia & Hypobetalipoproteinemia -- Drug-induced Dyslipidemia -- Lipodystrophies and Dyslipidemias -- Novel Genes for Dyslipidemias: Genome-Wide Association Studies -- Perspectives on Cholesterol Guidelines -- Nutrition and Coronary Heart Disease Prevention -- Phytosterol Therapy -- N-3 Fatty Acids: Role in Treating Dyslipidemias and Preventing Cardiovascular Disease -- Polyphenols for Cholesterol Management -- Dietary Supplements for Cholesterol Management -- Statins: Risk-Benefits and Role in Treating Dyslipidemias -- Fibrates: Risk-Benefits and Role in Treating Dyslipidemias -- Niacin: Risk-Benefits and Role in Treating Dyslipidemias -- Bile Acid Sequestrants: Risk-Benefits and Role in Treating Dyslipidemias -- Cholesterol Absorption Inhibitor-Ezetimibe: Risk-Benefits and Role in Treating Dyslipidemias -- Low Density Lipoprotein (LDL) Apheresis -- Novel Lipid Lowering Agents.
520 $a Dyslipidemias: Pathophysiology, Evaluation and Management provides a wealth of general and detailed guidelines for the clinical evaluation and management of lipid disorders in adults and children. Covering the full range of common through rare lipid disorders, this timely resource offers targeted, practical information for all clinicians who care for patients with dyslipidemias, including general internists, pediatric and adult endocrinologists, pediatricians, lipidologists, cardiologists, internists, and geneticists. For the last twenty years, there has been a growing recognition worldwide of the importance of managing dyslipidemia for the primary and secondary prevention of atherosclerotic vascular disease, especially coronary heart disease. This has been mainly due to the publication of the guidelines of National Cholesterol Education Program’s Adult Treatment Panel and Pediatric Panel from the United States. These guidelines have stimulated generation of similar recommendations from all over the world, particularly Europe, Canada, Australia and Asia. Developed by a renowned group of leading international experts, the book offers state-of-the-art chapters that are peer-reviewed and represent a comprehensive assessment of the field. A major addition to the literature, Dyslipidemias: Pathophysiology, Evaluation and Management is a gold-standard level reference for all clinicians who are challenged to provide the best care and new opportunities for patients with dyslipidemias.
650 0 $a Endocrinology . $3 1254221
650 0 $a Internal medicine. $3 644638
650 0 $a Primary care (Medicine). $3 1254357
650 0 $a Cardiology. $3 593957
650 0 $a Pediatrics. $3 644839
650 1 4 $a Endocrinology. $3 645497
650 2 4 $a Internal Medicine. $3 668583
650 2 4 $a Primary Care Medicine. $3 673694
700 1 $a Garg, Abhimanyu. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1260894
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9781607614258
776 0 8 $i Printed edition: $z 9781607614234
776 0 8 $i Printed edition: $z 9781493958528
830 0 $a Contemporary Endocrinology, $x 2523-3785 $3 1260895
856 4 0 $u https://doi.org/10.1007/978-1-60761-424-1
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)